BEIJING, March 29 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA),
a leading China-based vaccine manufacturer, announced today it has entered
into exclusive license, supply and distribution agreements with Parenteral
Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based
pharmaceutical company. Pursuant to the agreements, Parenteral is authorized
to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine)
and PANFLU.1 (H1N1 vaccine) to the government of India and private market in
India. Currently, the registration process is ongoing in India.
Parenteral intends to apply to the Drug Controller General of India (DCGI)
for the import approval for the vaccines. The volume, delivery schedule and
other specific details about how Sinovac's vaccines may be marketed and
supplied to the government of India and the private market in India have not
been determined.
Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The
agreements correspond with Sinovac's international marketing strategy to
partner with established local suppliers to secure regulatory approval and
more efficiently facilitate distribution in numerous international markets. We
look forward to partnering with Parenteral Biotech to bring our seasonal
influenza vaccine and H1N1 vaccine to the people of India."
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R)
(combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM)
(pandemic influenza (H5N1)), and PANFLU.1(TM) (pandemic influenza A (H1N1)).
Sinovac is developing vaccines for enterovirus 71, universal pandemic
influenza, pneumococcal infection, Japanese encephalitis, and human rabies.
Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
For more information, please contact:
Helen G. Yang
Sinovac Biotech Ltd.
Tel: +86-10-8289-0088 x9871
Fax: +86-10-6296-6910
Email: info@sinovac.com
Investors:
Amy Glynn/Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7023/7017
Email: aglynn@theruthgroup.com
scarrington@theruthgroup.com
Media
Janine McCargo
The Ruth Group
Tel: +1-656-536-7033
Email: jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.